NCT07010692View on ClinicalTrials.gov

Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 16, 2025

Primary Completion Date

May 31, 2030

Study Completion Date

June 30, 2030

Conditions
Keratinocyte CarcinomaBasal Cell CarcinomasSquamous Cell CarcinomaSkin Cancer
Interventions
DRUG

Tirbanibulin ointment 1%

Tirbanibulin ointment is applied for 5 nights following the in-office fractional laser procedure for patients with more advanced carcinomas.

DEVICE

non-ablative fractional laser

Every skin cancer will be treated with two wavelengths (1550nm and 1927nm) of a non-ablative fractional laser.

Trial Locations (1)

10022

RECRUITING

Bruce Robinson, MD, New York

All Listed Sponsors
lead

Bruce Robinson, MD

OTHER